About Us

Conference

Partner With Us

Home
Precision Medicine
Top Precision Medicine Solutions Providers in Europe

Top 10 Precision Medicine Solutions Providers in Europe – 2024

Imagine healthcare tailored down to the DNA level—where treatments are as unique as each individual's genetic makeup. This vision is turning into a tangible reality, thanks to pioneering precision medicine solutions providers throughout Europe. Harnessing cutting-edge tech advancements, innovators are rewriting the playbook on medical care.

The global precision medicine solutions providers market is projected to soar, reaching an estimated valuation of $75.30 billion by 2031. This growth, anticipated at a CAGR of 11.4 percent from 2024 to 2031, is driven by numerous advancements in precision medicine technologies.

Genomic sequencing is enabling precise identification of genetic variations that impact disease risk and treatment response, paving the way for personalized medicine. Biomarker analysis is gaining immense traction as it detects specific biological markers, guiding the development of targeted therapies and improving disease diagnosis. Meanwhile, artificial intelligence also facilitates more accurate predictions of disease progression and effective treatment plans by analyzing vast amounts of medical data seamlessly.

This edition of Life Sciences Review Europe presents a comprehensive overview of the latest developments in precision medicine across the continent, highlighting the innovative approaches, strategic collaborations, and regulatory landscapes shaping this transformative field.

It features insights from Silvy Mardiguian, Senior Director, Head of HEOR, Europe & New Markets at BeiGene, who highlights the disparities in availability of oncology products among different European countries, with some patients waiting significantly longer than others to access the same medicines. It also brings to light valuable insights from Nuala Trainor, director of innovation, personalized medicine at Lonza, who delves into the rapid growth and challenges of cell and gene therapies (CGTs), particularly focusing on chimeric antigen receptor (CAR) T cell immunotherapy for hematological malignancies.

In this edition highlighting the Top Precision Medicine Services in Europe 2024, we hope you find the best-suited solutions and innovations shaping the future of personalized healthcare.

Top 10 Precision Medicine Solutions Providers in Europe – 2024

Top Precision Medicine Solutions Providers in Europe

Oxford Global Marketing Ltd

Read full profile →

Oxford Global Marketing Ltd has been at the forefront of driving innovation, expertise, and partnership within the life sciences industry for over 15 years. As Oxford Global Marketing looks to 2025, the company is set to elevate its impact even further by merging its two leading series into the highly anticipated 'Precision Medicine' brand. ... read full profile

Idoven

Idoven is a health technology company focused on advancing cardiac care through artificial intelligence. They provide AI- powered tools that detect heart conditions early, enabling personalised treatment plans. By combining data science with cardiology expertise, Idoven aims to transform heart disease diagnosis and improve patient outcomes worldwide.

lifespin

lifespin is a deep data company creating an AI-based platform to measure and analyse metabolic data from patient samples. By mapping metabolomics, they provide valuable health insights applicable in diagnostics, patient stratification, personalised medicine, and drug discovery, serving pharmaceutical, research, and clinical settings.

Mindpeak

Mindpeak's mission is to enable personalised cancer treatment through Al-driven tissue diagnostics. Collaborating with pathology and university labs, their team of experts develops state-of-the-art automation tools for visual diagnosis. These tools alleviate the growing workload on cancer specialists by handling repetitive tasks, allowing experts to focus on critical, expertise-driven decisions.

Mirai Medical

Mirai Medical, with decades of expertise in pulsed electrical fields, electroporation, and immunotherapy, developed the unique ePORE therapy. This innovative outpatient solution simplifies cancer treatment and improves outcomes by targeting tumors anywhere on the body, reflecting Mirai Medical's commitment to enhancing patient experiences and advancing cancer care.

Owkin

Owkin is an AI biotechnology company dedicated to finding the right treatment for every patient. By combining human expertise with AI, Owkin accelerates drug discovery, clinical trials, and diagnostics. Through federated learning, they unlock insights from siloed data while protecting patient privacy, bringing new treatments and diagnostics to patients faster.

Pharming

Pharming is a global biopharmaceutical company focused on transforming the lives of patients with rare and severe diseases. They develop and commercialise a portfolio of innovative therapies, including protein replacements, small molecules, biologics, and gene therapies, spanning from early to late- stage development.

Scailyte

Scailyte, an ETH Zürich spin-off, uses AI to uncover complex disease patterns from single- cell data. Their ScaiVision platform reveals hidden cellular details, enabling ultra-sensitive diagnostics. With demonstrated clinical success and patent-pending biomarkers, Scailyte's pipeline includes projects in immunology, oncology, and women's health, supported by leading clinicians and exclusive datasets.

Stratipath

Stratipath utilises advanced deep learning (AI) to deliver cancer tumor risk profiling for healthcare and life science companies. Their cloud-based SaaS solutions, developed from years of groundbreaking research, are implemented in clinical settings, offering precision diagnostics to more patients at a lower cost and in significantly less time than traditional methods.

TAmiRNA

TAmiRNA is a biotech R&D company leveraging microRNA and RNAi technology to address unmet clinical needs. Specialising in minimal-invasive biomarkers, they excel in identifying and developing microRNA biomarkers for diagnosing and predicting disease and treatment responses, with a focus on musculoskeletal, cardiovascular, and metabolic diseases.